Probability of Having Non-Celiac Gluten Sensitivity

Non-celiac gluten sensitivity (NCGS) is estimated to affect approximately 6% of the US population (about 18 million people), making it significantly more common than celiac disease (which affects about 1%). Unlike celiac disease, NCGS does not cause intestinal damage or trigger the same autoimmune response, but it produces similar symptoms.

NCGS is characterized by intestinal and extra-intestinal symptoms (bloating, abdominal pain, diarrhea, headache, fatigue, joint pain, brain fog) that improve with a gluten-free diet and return when gluten is reintroduced. There is no reliable biomarker or diagnostic test; diagnosis is made by exclusion of celiac disease and wheat allergy, followed by a positive response to a gluten-free diet.

The condition remains somewhat controversial in the medical community, with some researchers questioning whether gluten itself is the culprit or whether other components of wheat (such as FODMAPs, amylase-trypsin inhibitors, or fructans) are responsible. A properly conducted double-blind gluten challenge is the gold standard for confirming the diagnosis. The gluten-free food market has grown to over $7 billion in the US, driven by both medically necessary and lifestyle-based demand.